Bispecific antibodies: A promising entrant in cancer immunotherapy

Saini, Samvedna; Kumar, Yatender

doi:10.1016/b978-0-12-821972-0.00014-9

Cited by 3 publications

(2 citation statements)

References 187 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Preliminary evidence may also support its efficacy in BCLs, such as DLBCL [ 93 ]. An attractive option for expanding the BiTE approach may be provided by re-engineering conventional mAbs that are already available [ 3 ].…”

Section: Antibody-directed Therapies For the Treatment Of Lymphomamentioning

confidence: 99%

“…Since that moment, an increasing number of mAbs have been developed for cancer treatment as a valid alternative to traditional cytotoxic agent-based chemotherapy, which is penalized by low tumor selectivity with consequent unwanted and harmful off-target effects. However, mAbs alone do not often provide sufficient cytotoxic effects, resulting in limited response when employed as monotherapy [ 3 ]. This holds true for the mAbs currently available in the setting of cutaneous lymphoma which achieve response in around half of patients, with ample variations according to stage and differential involvement of the skin and blood compartments [ 4 , 5 ].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Cutaneous Lymphoma and Antibody-Directed Therapies

et al. 2023

View full text Add to dashboard Cite

The introduction of monoclonal antibodies such as rituximab to the treatment of cancer has greatly advanced the treatment scenario in onco-hematology. However, the response to these agents may be limited by insufficient efficacy or resistance. Antibody–drug conjugates are an attractive strategy to deliver payloads of toxicity or radiation with high selectivity toward malignant targets and limited unwanted effects. Primary cutaneous lymphomas are a heterogeneous group of disorders and a current area of unmet need in dermato-oncology due to the limited options available for advanced cases. This review briefly summarizes our current understanding of T and B cell lymphomagenesis, with a focus on recognized molecular alterations that may provide investigative therapeutic targets. The authors reviewed antibody-directed therapies investigated in the setting of lymphoma: this term includes a broad spectrum of approaches, from antibody–drug conjugates such as brentuximab vedotin, to bi-specific antibodies, antibody combinations, antibody-conjugated nanotherapeutics, radioimmunotherapy and, finally, photoimmunotherapy with specific antibody–photoadsorber conjugates, as an attractive strategy in development for the future management of cutaneous lymphoma.

show abstract

Section: Antibody-directed Therapies For the Treatment Of Lymphomamentioning

confidence: 99%